{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:43:54Z","timestamp":1761648234273},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.bulcan.2014.12.003","type":"journal-article","created":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T20:24:11Z","timestamp":1421871851000},"page":"57-64","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prise en charge des cancers de la prostate m\u00e9tastatiques hormonosensibles (CPMHS)"],"prefix":"10.1016","volume":"102","author":[{"given":"Gwenaelle","family":"Gravis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naji","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Walz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2014.12.003_bib0005","series-title":"Les cancers en France\u00a0\u2013\u00a0\u00c9dition 2013\u00a0\u2013\u00a0Publications","year":"2013"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0010","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0015","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.urolonc.2005.09.003","article-title":"Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE","volume":"24","author":"Ryan","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0020","first-page":"293","article-title":"Studies on prostate cancer I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"19","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","article-title":"Studies on prostatic cancer II: the effects of castration on advanced carcinoma of the prostatic gland","volume":"43","author":"Huggins","year":"1941","journal-title":"Arch Surg"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0006-291X(71)90766-2","article-title":"Isolation and properties of the FSH and LH-releasing hormone","volume":"43","author":"Schally","year":"1971","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0035","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0040","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials","volume":"355","author":"Prostate Cancer Trialists\u2019 Collaborative Group","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00345-007-0158-7","article-title":"Optimal treatment of locally advanced prostate cancer","volume":"25","author":"Wirth","year":"2007","journal-title":"World J Urol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0050","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0060","first-page":"687","article-title":"Endocrine complications of androgen deprivation therapy in men with prostate cancer","volume":"4","author":"Harle","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x","article-title":"Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial","volume":"79","author":"The Medical Research Council Prostate Cancer Working Party Investigators Group","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0070","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00345-013-1144-x","article-title":"Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma","volume":"32","author":"Prezioso","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0075","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z","article-title":"Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen","volume":"71","author":"Akakura","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0080","first-page":"2275","article-title":"Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma","volume":"50","author":"Bruchovsky","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0085","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0090","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.eururo.2013.04.020","article-title":"Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3\u00a0trials","volume":"64","author":"Sciarra","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0095","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.juro.2012.06.046","article-title":"Improved overall survival trends of men with newly diagnosed M1\u00a0prostate cancer: a SWOG phase III trial experience (S8494, S8894\u00a0and S9346)","volume":"188","author":"Tangen","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1046\/j.1464-410x.2000.00894.x","article-title":"Adjuvant mitozantrone chemotherapy in advanced prostate cancer","volume":"86","author":"Wang","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0105","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0110","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0115","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1200\/JCO.2007.15.9830","article-title":"Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer","volume":"26","author":"Millikan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0120","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3\u00a0trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0125","first-page":"LBA2","article-title":"Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial","volume":"32","author":"Sweeney","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0022-5347(05)64059-1","article-title":"Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning","volume":"169","author":"Glass","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0135","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","article-title":"Flexible trial design in practice\u00a0\u2013\u00a0Stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial","volume":"13","author":"Sydes","year":"2012","journal-title":"Trials"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0140","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"Eisenberger","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2014.09.022","article-title":"Prognostic factors for survival in non-castrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model","author":"Gravis","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0150","first-page":"95","article-title":"Highly functional natural killer (NK) cells as predictive biomarkers associated with long response to castration in newly diagnosed metastatic prostate cancer","volume":"32","author":"Pasero","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0155","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04\u00a0and PR05\u00a0randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0160","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0165","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-014-1347-9","article-title":"The oncologic role of local treatment in primary metastatic prostate cancer","author":"Ghadjar","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0170","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","article-title":"Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study","volume":"65","author":"Culp","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.bulcan.2014.12.003_bib0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clgc.2012.08.003","article-title":"Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy","volume":"11","author":"Berkovic","year":"2013","journal-title":"Clin Genitourin Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455114000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455114000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T05:24:20Z","timestamp":1537939460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455114000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0007455114000046"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2014.12.003","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge des cancers de la prostate m\u00e9tastatiques hormonosensibles (CPMHS)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2014.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}